Rupee weakens slightly, broad dollar softness cushions pressure
The rupee closed at 86.2925 against the U.S. dollar, down about 0.2% on the day, after touching a near one-month low of 86.35 earlier in the session.
Explore courses from Top Institutes in
Select a Course Category
Design Thinking
Data Science
Public Policy
PGDM
Cybersecurity
Management
Project Management
Product Management
Finance
Healthcare
Data Science
MBA
healthcare
Degree
Leadership
Technology
Artificial Intelligence
CXO
Others
MCA
Digital Marketing
Data Analytics
Operations Management
others
Skills you'll gain:
Duration:
22 Weeks
IIM Indore
CERT-IIMI DTAI Async India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
25 Weeks
IIM Kozhikode
CERT-IIMK PCP DTIM Async India
Starts on
undefined
Get Details
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Libas Purple Days Sale
Libas
Undo
Asian currencies were flat-to-slightly higher, while the dollar index declined by nearly 0.2% to 98.2.
The Indian rupee and the Indonesian rupiah are among the few regional currencies nursing losses on the year so far, even as their peers, such as the Taiwan dollar and the Korean won, have climbed over 11% and 6%, respectively.
Muted portfolio flows, India's external investment deficit and likely FX reserve accumulation by the Reserve
Bank
of India are among the reasons cited by analysts for rupee's lacklustre performance this year.
Live Events
On the day, price action appeared to indicate modest outflows but dollar-buying pressure eased in the latter half of the session, helping the rupee trim its losses, a trader at a private bank said.
India's benchmark
equity
indexes, the BSE Sensex and Nifty 50, closed higher by about 0.5% each on the day, while the benchmark 10-year bond yield was last quoted slightly lower at 6.2986%.
In the near term, focus will be on developments on two fronts: how U.S. economic data impact expectations of rate cuts and news surrounding U.S.-India trade negotiations ahead of the August 1 deadline for higher U.S. tariffs to take effect.
"We maintain our view that slower growth, profit margin compression and export price reduction will contain the impact of tariffs, and that a slower economy will justify the Fed resuming rate cuts in September," ANZ said in a Monday note.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
4 minutes ago
- New Indian Express
Trump tariff move unlikely to derail Tamil Nadu's industrial ambitions: Industries Minister Rajaa
CHENNAI: Tamil Nadu is prepared to absorb the impact of new US tariffs, State Industries Minister Dr TRB Rajaa said on Thursday, after US President Donald Trump announced a 25% duty on goods imported from India, escalating trade tensions between the two countries. Speaking on the sidelines of the second edition of Passenger Vehicle Expo, Rajaa said India's most industrialised state had already laid contingency plans to shield key sectors such as manufacturing, textiles, and footwear from sudden trade shocks. 'We've seen the Covid impact, we've seen global disruptions,' he said. 'If there's one state that's resilient enough to weather this, it's Tamil Nadu.' Rajaa said he was 'unhappy' with Trump's rhetoric. 'As an Indian, and as a representative of Tamil Nadu, I found the language disturbing. But we will stand by the Union government and hope the Prime Minister and his Cabinet respond with wisdom, balancing the interests of our farmers, the primary sector, and industry.' He also warned against overinterpreting the tariff move based on a single post. 'This is diplomacy in trade between two of the world's largest economies,' he said. 'It's unfortunate the US President chose such a platform for such a major announcement. But I trust Prime Minister Narendra Modi will respond in the appropriate format.'
The Wire
4 minutes ago
- The Wire
From ‘Howdy Modi' to ‘Cannot Name Trump': How Modi Has Taken a Hit from Trump's Tariffs and Taunts
Trump's actions hit directly at the pillars propping up Modi's domestic political strength in ways visible and hard to immediately fix. Prime Minister Modi, accompanied by US President Donald Trump, writes in the visitor's book at the White House. Photo: Press Information Bureau/GODL. New Delhi: US President Donald Trump's announcement of steep tariffs on India, his criticism of the Indian economy as "dead" and his public overtures towards Pakistan have placed Prime Minister Narendra Modi, more than India as a nation, in a uniquely difficult spot. While the impact on India as a country is tangible, it is a moment of political reckoning for Modi, who has been under pressure since the 2024 Lok Sabha elections when the BJP lost its majority in the house. Here are the reasons it places Modi in a tough spot. Destroys Modi's domestic image of a global statesman Modi has painstakingly cultivated an image of himself domestically as a top global leader exhibiting close personal friendships with the world's most influential heads of state, particularly in the US. Trump's public insults and punitive tariffs undermine this persona, making Modi appear ineffective or even powerless in protecting Indian interests and standing on the world stage. Under pressure from the US, he has already succumbed to China, even though Beijing continues to pile on pressure and refuses to make any concessions. This severely erodes Modi's political brand at home, where he and his party have used images from his foreign trips to project influence domestically. Political ammunition for domestic opposition With Trump – the first for an American president – openly criticising the Indian economy and labelling it 'dead', opposition parties such as the Congress have seized upon these remarks to portray Modi's economic approach and foreign outreach as failures. They argue that Modi's support of Trump during previous years has unravelled, leaving India diplomatically isolated and economically vulnerable. Modi's failure to name Trump in his Lok Sabha speech, despite an open challenge by leader of opposition Rahul Gandhi, has shown him as weak and scared of standing up to the US president. This provides ammunition for the opposition parties to politically target Modi when he is already being challenged by the Rashtriya Swayamsevak Sangh on the issue of the election of the new BJP president. Setbacks undermine Modi's central arguments The new US tariffs threaten to erode the competitiveness of Indian exports, damage investor sentiment and threaten to bury Modi's faltering attempts to get global manufacturing to India. Key labour-intensive sectors such as jewellery, textiles and certain electronics face certain job losses. These outcomes create immediate economic pain and threaten Modi's narrative of making India an economic powerhouse as the 'fourth-largest economy in the world'. If the US also follows through on penalties related to India's Russia policy, the fallout could be even more severe. Energy prices could rise and India's fiscal deficit could increase, putting further pressure on the budget and bringing greater distress to the people. Hyphenation with Pakistan sours nationalist dreams Trump's statements and overtures that club India with Pakistan, including praising a new US-Pakistan energy deal and openly patronising Islamabad, are a direct affront to Modi's narrative of India as a regional counterweight to both Pakistan and China. The perception that the US is tilting toward Pakistan, or using India-Pakistan tensions for leverage, is particularly damaging to Modi's core nationalist constituency, which takes pride in a strong, singular global standing for India. It believed that India cannot be equated with its neighbour or seen as needing US mediation to end the conflict. Modi's inability to secure even this basic gain of the UPA era damages his ' desh nahi jhukne doonga ' brand among his core Hindutva supporters. Loss of bargaining leverage hurts economy Modi's strategy had relied on fostering goodwill and leveraging the India-US relationship for favourable trade agreements and strategic cooperation. Trump's abrupt imposition of tariffs, at rates higher than those faced by competing Asian economies, signals that Washington is willing to use harsh tactics, regardless of personal or diplomatic ties. This despite Modi rushing to meet Trump after his re-election early this year. New Delhi is now left scrambling for a response, with very limited leverage, and must consider politically costly concessions or risk a further downturn in exports and economic growth. After 11 years of being in power, Modi can't shift the blame on anyone else and will be held accountable for the severe economic downturn in the public eye. In sum, Trump's actions and rhetoric hit directly at pillars propping Modi's domestic political strength and standing, in ways that are both visible and hard to quickly repair. The impact on India will be managed, but it is Modi, as a political leader and as an electoral brand, who now faces the greatest challenge in his eleven years in office. The Wire is now on WhatsApp. Follow our channel for sharp analysis and opinions on the latest developments.
Hans India
4 minutes ago
- Hans India
Agilent Supports India's Global Biopharma Ambitions with State-of-the-Art Experience Center in Hyderabad
Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, today announced the inauguration of its new Biopharma Experience Center in Hyderabad, Telangana. The facility marks a significant investment in India's rapidly growing life sciences ecosystem and reflects Agilent's long-term commitment to advancing biopharmaceutical innovation both locally and globally. The center was inaugurated by Shri Duddila Sridhar Babu, Hon'ble Minister for Information Technology, Electronics, Communications, and Industries, Government of Telangana, in the presence of Agilent President and CEO Padraig McDonnell, along with senior leaders from India's pharmaceutical and biopharma sectors. The new Agilent Biopharma Experience Center in Hyderabad presents a major opportunity to accelerate the city's leadership in life sciences and healthcare innovation. Designed to support the full drug development journey, the center brings together advanced lab technologies, expert training, and regulatory-ready workflows to help researchers, scientists, and companies develop high-quality, life-saving medicines faster and more efficiently. It offers end-to-end solutions across key modalities such as chromatography, mass spectrometry, cell analysis, and lab informatics, allowing companies to simulate real lab environments, test for quality and compliance, and co-create market-ready solutions tailored to both Indian and global needs. For Hyderabad's vibrant ecosystem of startups, academic institutions, and skilled professionals, the center unlocks direct access to global expertise, cutting-edge instrumentation, and real-world application environments. It supports faster R&D, hands-on training aligned with international regulatory standards, and stronger collaboration between industry and academia. By addressing critical challenges in biosimilars, biologics, and precision medicine, the facility strengthens Hyderabad's position as a trusted global hub for next-generation drug development, and a key contributor to India's biopharma growth story. 'India is a strategic growth market for Agilent, and Hyderabad is at the forefront of biopharma innovation,' said Padraig McDonnell, CEO, Agilent Technologies. 'Our future will be defined by continued innovation and a relentless focus on our customers. This new center reflects our commitment to delivering integrated solutions that help bring life-changing therapies to market faster and more efficiently. It also reinforces our support for the 'Make-in-India' initiative by empowering local innovation, nurturing talent, and enabling scalable, affordable, and sustainable solutions.' Located in the heart of India's life sciences capital, the center is designed to address critical gaps in analytical capabilities and regulatory readiness for biopharma companies. It will serve as a hub for innovation and collaboration, supporting the development of biologics, biosimilars, and precision medicine. Shri Duddila Sridhar Babu, Hon'ble Minister for Information Technology, Electronics, Communications, and Industries, Government of Telangana said, 'Hyderabad has emerged as a complete healthcare and life sciences ecosystem—from drug discovery and clinical trials to world-class hospitals and affordable, high-quality patient care. We are proud to host eight of the top ten global pharma companies, five of India's leading healthcare chains, and over 230 USFDA-approved manufacturing facilities. Contributing nearly one-third of India's pharmaceutical production and 40% of bulk drug exports, Telangana is making a strong impact both nationally and globally. With a strong talent base and a clear focus on innovation, we are building a future-ready healthcare system. The launch of the Agilent Biopharma Experience Center is a significant milestone in strengthening Telangana's position as a global leader in life sciences, and a valuable addition to our expanding innovation-driven ecosystem.' Hyderabad offers one of the most mature and future-focused life sciences ecosystems in India, combining deep industry expertise, strong R&D capabilities, and a supportive policy environment. With its legacy in generics and a growing focus on advanced therapies, the city is well-positioned for the next phase of healthcare innovation. The launch of the Agilent Biopharma Experience Center builds on this foundation, introducing advanced analytical and regulatory capabilities that support both local innovation and global delivery. This capital investment is part of Agilent's broader three-to-five-year India growth strategy, which includes expanding its footprint, deepening customer partnerships, and positioning India as a strategic hub in Agilent's global innovation and profitability roadmap. The India Solution Center in Manesar, launched earlier this year, further reflects this ongoing commitment—contributing to Agilent's efforts to enhance its presence and capabilities in one of its fastest-growing, high-priority markets globally. 'Agilent is already working closely with many of India's leading biopharma companies,' added McDonnell. 'With this center, we aim to strengthen those relationships and co-create solutions that meet the evolving needs of the Indian and global markets.' This milestone marks a new chapter in Agilent's journey with India—deepening collaboration, accelerating innovation, and contributing to a healthier, more sustainable future.
